Detail publikace

In vivo biocompatibility of site-directed apoferritin-based nanocarrier for cardiotoxic antitumour drug doxorubicin

DOSTÁLOVÁ, S. POLANSKÁ, H. SVOBODOVÁ, M. BALVAN, J. KRYŠTOFOVÁ, O. MASAŘÍK, M. ECKSCHLAGER, T. STIBOROVÁ, M. HEGER, Z. ADAM, V.

Originální název

In vivo biocompatibility of site-directed apoferritin-based nanocarrier for cardiotoxic antitumour drug doxorubicin

Typ

článek ve sborníku ve WoS nebo Scopus

Jazyk

angličtina

Originální abstrakt

Doxorubicin (DOX), a potent anthracycline antibiotic [1], is used in conventional cancer therapy for the treatment of various solid and haematological malignancies, such as breast [2], lung [3], bladder [4] or Hodgkin lymphoma [5]. However, up to 26% of patients treated with DOX develop arrhythmia or cardiomyopathy [6]. Co-administration with cardioprotective drugs can lead to other unwanted side effects, such as the development of secondary malignancies in case of dexrazoxane [7]. This effectively limits DOX dose that can be administered to the patients [6].

Klíčová slova

Doxorubicin (DOX); cancer cells; nanocarrier

Autoři

DOSTÁLOVÁ, S.; POLANSKÁ, H.; SVOBODOVÁ, M.; BALVAN, J.; KRYŠTOFOVÁ, O.; MASAŘÍK, M.; ECKSCHLAGER, T.; STIBOROVÁ, M.; HEGER, Z.; ADAM, V.

Vydáno

10. 5. 2017

ISSN

2296-9667

Periodikum

European & Global Summit for Clinical Nanomedicine and Targeted Medicine

Stát

Švýcarská konfederace

Strany od

168

Strany do

169

Strany počet

2

BibTex

@inproceedings{BUT141783,
  author="Simona {Dostálová} and Hana {Polanská} and Markéta {Svobodová} and Jan {Balvan} and Olga {Kryštofová} and Michal {Masařík} and Tomáš {Eckschlager} and Marie {Stiborová} and Zbyněk {Heger} and Vojtěch {Adam}",
  title="In vivo biocompatibility of site-directed apoferritin-based nanocarrier for cardiotoxic antitumour drug doxorubicin",
  booktitle="10th European and Global Summit for Clinical Nanomedicine and Targeted Medicine: witnessing the solutions and tackling the hurdles",
  year="2017",
  journal="European & Global Summit for Clinical Nanomedicine and Targeted Medicine",
  pages="168--169",
  issn="2296-9667"
}